Scilex Gets Orphan Drug Designation for Its Version of Colchicine

Dow Jones

04-17

By Josh Beckerman

Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis.

The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares.

Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday.

The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

April 16, 2025 14:39 ET (18:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2528279819"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2528279819\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2528279819?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 02:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528279819","market":"sg","top_or_hot":-1,"title":"Scilex Gets Orphan Drug Designation for Its Version of Colchicine","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n</p>\n<p>\n  The company's Gloperba, licensed from Romeg <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n</p>\n<p>\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n</p>\n<p>\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 14:39 ET (18:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scilex Gets Orphan Drug Designation for Its Version of Colchicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScilex Gets Orphan Drug Designation for Its Version of Colchicine\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-17 02:39</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n</p>\n<p>\n  The company's Gloperba, licensed from Romeg <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n</p>\n<p>\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n</p>\n<p>\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 14:39 ET (18:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2528279819","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528279819","pubTimestamp":1744828740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis.The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares.Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday.The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SCLX":"Scilex Holding Company"},"translate_title":"Scilex的秋水仙碱获得孤儿药称号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SCLX":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Scilex Holding said the Food and Drug Administration granted orphan drug designation for colchicine for the treatment of pericarditis. \n\n\n  The company's Gloperba, licensed from Romeg Therapeutics, is a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares. \n\n\n  Scilex shares were recently down 7% to $6.43, recovering from a 52-week low of $5.90 earlier Wednesday. \n\n\n  The Orphan Drug Act, from 1983, created financial incentives for development of drugs that treat rare diseases. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 14:39 ET (18:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}